The present invention relates generally to medical devices used for accessing, visualizing, and/or treating regions of tissue within a body. More particularly, the present invention relates to methods and apparatus for the delivery of ablation energy, such as radio-frequency (RF) ablation, to an underlying target tissue utilizing a bipolar electrode configuration for treatment in a controlled manner, while directly visualizing the tissue.
Conventional devices for visualizing interior regions of a body lumen are known. For example, ultrasound devices have been used to produce images from within a body in vivo. Ultrasound has been used both with and without contrast agents, which typically enhance ultrasound-derived images.
Other conventional methods have utilized catheters or probes having position sensors deployed within the body lumen, such as the interior of a cardiac chamber. These types of positional sensors are typically used to determine the movement of a cardiac tissue surface or the electrical activity within the cardiac tissue. When a sufficient number of points have been sampled by the sensors, a “map” of the cardiac tissue may be generated.
Another conventional device utilizes an inflatable balloon which is typically introduced intravascularly in a deflated state and then inflated against the tissue region to be examined. Imaging is typically accomplished by an optical fiber or other apparatus such as electronic chips for viewing the tissue through the membrane(s) of the inflated balloon. Moreover, the balloon must generally be inflated for imaging. Other conventional balloons utilize a cavity or depression formed at a distal end of the inflated balloon. This cavity or depression is pressed against the tissue to be examined and is flushed with a clear fluid to provide a clear pathway through the blood.
However, such imaging balloons have many inherent disadvantages. For instance, such balloons generally require that the balloon be inflated to a relatively large size which may undesirably displace surrounding tissue and interfere with fine positioning of the imaging system against the tissue. Moreover, the working area created by such inflatable balloons are generally cramped and limited in size. Furthermore, inflated balloons may be susceptible to pressure changes in the surrounding fluid. For example, if the environment surrounding the inflated balloon undergoes pressure changes, e.g., during systolic and diastolic pressure cycles in a beating heart, the constant pressure change may affect the inflated balloon volume and its positioning to produce unsteady or undesirable conditions for optimal tissue imaging. Additionally, imaging balloons are subject to producing poor or blurred tissue images if the balloon is not firmly pressed against the tissue surface because of intervening blood between the balloon and tissue.
Accordingly, these types of imaging modalities are generally unable to provide desirable images useful for sufficient diagnosis and therapy of the endoluminal structure, due in part to factors such as dynamic forces generated by the natural movement of the heart. Moreover, anatomic structures within the body can occlude or obstruct the image acquisition process. Also, the presence and movement of opaque bodily fluids such as blood generally make in vivo imaging of tissue regions within the heart difficult.
Other external imaging modalities are also conventionally utilized. For example, computed tomography (CT) and magnetic resonance imaging (MRI) are typical modalities which are widely used to obtain images of body lumens such as the interior chambers of the heart. However, such imaging modalities fail to provide real-time imaging for intra-operative therapeutic procedures. Fluoroscopic imaging, for instance, is widely used to identify anatomic landmarks within the heart and other regions of the body. However, fluoroscopy fails to provide an accurate image of the tissue quality or surface and also fails to provide for instrumentation for performing tissue manipulation or other therapeutic procedures upon the visualized tissue regions. In addition, fluoroscopy provides a shadow of the intervening tissue onto a plate or sensor when it may be desirable to view the intraluminal surface of the tissue to diagnose pathologies or to perform some form of therapy on it.
Thus, a tissue imaging system which is able to provide real-time in vivo images of tissue regions within body lumens such as the heart through opaque media such as blood and which also provide instruments for therapeutic procedures upon the visualized tissue are desirable.
A tissue imaging and manipulation apparatus that may be utilized for procedures within a body lumen, such as the heart, in which visualization of the surrounding tissue is made difficult, if not impossible, by medium contained within the lumen such as blood, is described below. Generally, such a tissue imaging and manipulation apparatus comprises an optional delivery catheter or sheath through which a deployment catheter and imaging hood may be advanced for placement against or adjacent to the tissue to be imaged.
The deployment catheter may define a fluid delivery lumen therethrough as well as an imaging lumen within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, the imaging hood may be expanded into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field is defined by the imaging hood. The open area is the area within which the tissue region of interest may be imaged. The imaging hood may also define an atraumatic contact lip or edge for placement or abutment against the tissue region of interest. Moreover, the distal end of the deployment catheter or separate manipulatable catheters may be articulated through various controlling mechanisms such as push-pull wires manually or via computer control
The deployment catheter may also be stabilized relative to the tissue surface through various methods. For instance, inflatable stabilizing balloons positioned along a length of the catheter may be utilized, or tissue engagement anchors may be passed through or along the deployment catheter for temporary engagement of the underlying tissue.
In operation, after the imaging hood has been deployed, fluid may be pumped at a positive pressure through the fluid delivery lumen until the fluid fills the open area completely and displaces any blood from within the open area. The fluid may comprise any biocompatible fluid, e.g., saline, water, plasma, Fluorinert™, etc., which is sufficiently transparent to allow for relatively undistorted visualization through the fluid. The fluid may be pumped continuously or intermittently to allow for image capture by an optional processor which may be in communication with the assembly.
In an exemplary variation for imaging tissue surfaces within a heart chamber containing blood, the tissue imaging and treatment system may generally comprise a catheter body having a lumen defined therethrough, a visualization element disposed adjacent the catheter body, the visualization element having a field of view, a transparent fluid source in fluid communication with the lumen, and a barrier or membrane extendable from the catheter body to localize, between the visualization element and the field of view, displacement of blood by transparent fluid that flows from the lumen, and an instrument translatable through the displaced blood for performing any number of treatments upon the tissue surface within the field of view. The imaging hood may be formed into any number of configurations and the imaging assembly may also be utilized with any number of therapeutic tools which may be deployed through the deployment catheter.
More particularly in certain variations, the tissue visualization system may comprise components including the imaging hood, where the hood may further include a membrane having a main aperture and additional optional openings disposed over the distal end of the hood. An introducer sheath or the deployment catheter upon which the imaging hood is disposed may further comprise a steerable segment made of multiple adjacent links which are pivotably connected to one another and which may be articulated within a single plane or multiple planes. The deployment catheter itself may be comprised of a multiple lumen extrusion, such as a four-lumen catheter extrusion, which is reinforced with braided stainless steel fibers to provide structural support. The proximal end of the catheter may be coupled to a handle for manipulation and articulation of the system.
To provide visualization, an imaging element such as a fiberscope or electronic imager such as a solid state camera, e.g., CCD or CMOS, may be mounted, e.g., on a shape memory wire, and positioned within or along the hood interior. A fluid reservoir and/or pump (e.g., syringe, pressurized intravenous bag, etc.) may be fluidly coupled to the proximal end of the catheter to hold the translucent fluid such as saline or contrast medium as well as for providing the pressure to inject the fluid into the imaging hood.
In treating tissue regions which are directly visualized, as described above, treatments utilizing electrical energy may be employed to ablate the underlying visualized tissue. Many ablative systems typically employ electrodes arranged in a monopolar configuration where a single electrode is positioned proximate to or directly against the tissue to be treated within the patient body and a return electrode is located external to the patient body. Utilization of bipolar electrode ablation removes the need for a return or grounding electrode to be adhered to the skin of the patient and may further allow for a more precise delivery of ablation energy over a small target area for creation of precise lesions.
In particular, such assemblies, apparatus, and methods may be utilized for treatment of various conditions, e.g., arrhythmias, through ablation under direct visualization. Variations of the tissue imaging and manipulation apparatus may be configured to facilitate the application of bipolar energy delivery, such as radio-frequency (RF) ablation, to an underlying target tissue for treatment in a controlled manner while directly visualizing the tissue during the bipolar ablation process as well as confirming (visually and otherwise) appropriate treatment thereafter.
Various configurations may be utilized for a bipolar electrode arrangement which allows for bipolar ablation of tissue within the visual field being imaged via an imaging element. The current may be conducted between the electrodes through the transparent saline fluid infused into and through the hood. One example may include a first electrode positioned within or along the imaging hood and a second electrode positioned along the distal membrane of hood. The electrode along the hood membrane may be in a number of different configurations such as a ring electrode. Alternatively, two or more electrodes may be positioned in various arrangements over the membrane.
In other variations, the hood (or balloon in other variations) may be internally segmented into two or more separated chambers where saline fluid having opposite charges may be introduced into each respective chamber for bipolar ablation. Each chamber may define a corresponding first and second aperture over the distal membrane and may also each have a corresponding first and second electrode positioned within each respective chamber. Each electrode may be positioned within the chambers via respective first and second electrode support members. The transparent fluid may be introduced into each chamber past the electrodes such that the charged fluid passing through their respective apertures may contact one another over the tissue to conduct energy therebetween and ablate the underlying tissue. In another variation, rather than utilizing two separate chambers, a second inner hood may be positioned within the visualization hood to achieve the same or similar electrode arrangement.
In yet other variations, one or more of the support struts may be configured as electrodes well. The current may flow between the respective support struts or between a first electrode and one or more of the support struts. In yet additional variations, a bipolar electrode arrangement may be positioned along the hood and/or hood membrane such that tissue drawn into the hood or portions thereof may be ablated accordingly. In drawing portions of tissue relative to the hood, various instruments, such as tissue graspers, may also be utilized and optionally configured as an electrode as well.
Other variations may also include one or more struts having conductive tips which are configured to extend distally and project past the hood. In use, as the underlying tissue is visualized, as previously described, the one or more conducting tips may be extended distally into the tissue region surrounding the hood and contacted against the tissue surface and the conducting fluid may be infused into hood and into the area immediately surrounding the hood. The ablation energy may be thus conducted between a first electrode and the one or more conducting tips to ablate the tissue therebetween.
Additional instruments such as needles or needle assemblies may be advanced into the underlying tissue being visualized. The one or more needles may be configured as electrodes as well to allow for conduction into the underlying tissue for creating transmural lesions. Aside from needles, other instruments such as expandable anchors or ablation probe members may alternatively be utilized.
In yet other variations, a return electrode may be positioned proximally of the hood, e.g., along the deployment catheter or outer sheath. In such an arrangement, the return electrode may be positioned along a first tissue region, such as an atrial septum, while the first electrode is advanced distally such as in a left atrium of the heart. Conduction between the electrodes may thus be effected to ablate the tissue underlying and/or surrounding the electrode arrangement. In other variations, a separate instrument incorporating a return electrode may be advanced within the patient body, e.g., intravascularly or through a body cavity, and positioned in proximity to the electrode to effect ablation of the tissue region surrounding or in proximity to the electrodes.
In a further variation, ablation energy may be controlled utilizing parameters such as the salinity concentration of saline or by controlling the temperature of the transparent saline fluid, which is also utilized for visualization.
A tissue-imaging and manipulation apparatus described herein is able to provide real-time images in vivo of tissue regions within a body lumen such as a heart, which is filled with blood flowing dynamically therethrough and is also able to provide intravascular tools and instruments for performing various procedures upon the imaged tissue regions. Such an apparatus may be utilized for many procedures, e.g., facilitating transseptal access to the left atrium, cannulating the coronary sinus, diagnosis of valve regurgitation/stenosis, valvuloplasty, atrial appendage closure, arrhythmogenic focus ablation, among other procedures.
One variation of a tissue access and imaging apparatus is shown in the detail perspective views of
When the imaging and manipulation assembly 10 is ready to be utilized for imaging tissue, imaging hood 12 may be advanced relative to catheter 14 and deployed from a distal opening of catheter 14, as shown by the arrow. Upon deployment, imaging hood 12 may be unconstrained to expand or open into a deployed imaging configuration, as shown in
Imaging hood 12 may be attached at interface 24 to a deployment catheter 16 which may be translated independently of deployment catheter or sheath 14. Attachment of interface 24 may be accomplished through any number of conventional methods. Deployment catheter 16 may define a fluid delivery lumen 18 as well as an imaging lumen 20 within which an optical imaging fiber or assembly may be disposed for imaging tissue. When deployed, imaging hood 12 may expand into any number of shapes, e.g., cylindrical, conical as shown, semi-spherical, etc., provided that an open area or field 26 is defined by imaging hood 12. The open area 26 is the area within which the tissue region of interest may be imaged. Imaging hood 12 may also define an atraumatic contact lip or edge 22 for placement or abutment against the tissue region of interest. Moreover, the diameter of imaging hood 12 at its maximum fully deployed diameter, e.g., at contact lip or edge 22, is typically greater relative to a diameter of the deployment catheter 16 (although a diameter of contact lip or edge 22 may be made to have a smaller or equal diameter of deployment catheter 16). For instance, the contact edge diameter may range anywhere from 1 to 5 times (or even greater, as practicable) a diameter of deployment catheter 16.
As seen in the example of
Although contact edge 22 need not directly contact the underlying tissue, it is at least preferably brought into close proximity to the tissue such that the flow of clear fluid 28 from open area 26 may be maintained to inhibit significant backflow of blood 30 back into open area 26. Contact edge 22 may also be made of a soft elastomeric material such as certain soft grades of silicone or polyurethane, as typically known, to help contact edge 22 conform to an uneven or rough underlying anatomical tissue surface. Once the blood 30 has been displaced from imaging hood 12, an image may then be viewed of the underlying tissue through the clear fluid 30. This image may then be recorded or available for real-time viewing for performing a therapeutic procedure. The positive flow of fluid 28 may be maintained continuously to provide for clear viewing of the underlying tissue. Alternatively, the fluid 28 may be pumped temporarily or sporadically only until a clear view of the tissue is available to be imaged and recorded, at which point the fluid flow 28 may cease and blood 30 may be allowed to seep or flow back into imaging hood 12. This process may be repeated a number of times at the same tissue region or at multiple tissue regions.
In utilizing the imaging hood 12 in any one of the procedures described herein, the hood 12 may have an open field which is uncovered and clear to provide direct tissue contact between the hood interior and the underlying tissue to effect any number of treatments upon the tissue, as described above. Yet in additional variations, imaging hood 12 may utilize other configurations. An additional variation of the imaging hood 12 is shown in the perspective and end views, respectively, of
Aperture 42 may function generally as a restricting passageway to reduce the rate of fluid out-flow from the hood 12 when the interior of the hood 12 is infused with the clear fluid through which underlying tissue regions may be visualized. Aside from restricting out-flow of clear fluid from within hood 12, aperture 42 may also restrict external surrounding fluids from entering hood 12 too rapidly. The reduction in the rate of fluid out-flow from the hood and blood in-flow into the hood may improve visualization conditions as hood 12 may be more readily filled with transparent fluid rather than being filled by opaque blood which may obstruct direct visualization by the visualization instruments.
Moreover, aperture 42 may be aligned with catheter 16 such that any instruments (e.g., piercing instruments, guidewires, tissue engagers, etc.) that are advanced into the hood interior may directly access the underlying tissue uninhibited or unrestricted for treatment through aperture 42. In other variations wherein aperture 42 may not be aligned with catheter 16, instruments passed through catheter 16 may still access the underlying tissue by simply piercing through membrane 40.
In an additional variation,
Additional details of tissue imaging and manipulation systems and methods which may be utilized with apparatus and methods described herein are further described, for example, in U.S. patent application Ser. No. 11/259,498 filed Oct. 25, 2005 (U.S. Pat. Pub. No. 2006/0184048 A1); 11/763,399 filed Jun. 14, 2007 (U.S. Pat. Pub. No. 2007/0293724 A1); and also in 11/828,267 filed Jul. 25, 2007 (U.S. Pat. Pub. No. 2008/0033290 A1), and 11/775,837 filed Jul. 10, 2007 (U.S. Pat. Pub. No. 2008/0009747 A1) each of which is incorporated herein by reference in its entirety.
In treating tissue regions which are directly visualized, as described above, treatments utilizing electrical energy may be employed to ablate the underlying visualized tissue. Many ablative systems typically employ electrodes arranged in a monopolar configuration where a single electrode is positioned proximate to or directly against the tissue to be treated within the patient body and a return electrode is located external to the patient body. The assembly illustrated in
In particular, such assemblies, apparatus, and methods may be utilized for treatment of various conditions, e.g., arrhythmias, through ablation under direct visualization. Details of examples for the treatment of arrhythmias under direct visualization which may be utilized with apparatus and methods described herein are described, for example, in U.S. patent application Ser. No. 11/775,819 filed Jul. 10, 2007 (U.S. Pat. Pub. No. 2008/0015569 A1), which is incorporated herein by reference in its entirety. Variations of the tissue imaging and manipulation apparatus may be configured to facilitate the application of bipolar energy delivery, such as radio-frequency (RF) ablation, to an underlying target tissue for treatment in a controlled manner while directly visualizing the tissue during the bipolar ablation process as well as confirming (visually and otherwise) appropriate treatment thereafter.
As shown, bipolar ablation and visualization catheter assembly 50 illustrates one variation where the visualization hood 12 may incorporate a bipolar ablation assembly 52 within and/or along the hood 12. The assembly 50 is further illustrated where bipolar ablation assembly 52 may be coupled or otherwise in electrical communication with power generator 56 (e.g., RF power generator) through deployment catheter 16 and handle 54 via cable 58. Fluid reservoir 60 is also illustrated as being coupled to handle 54 and in fluid communication with hood 12 as well as image display assembly 62 which may be coupled to an optical fiber bundle or to an electronic imaging sensor (e.g., CCD or CMOS imager) positioned within or along hood 12 for visualizing the underlying tissue, as described above.
Bipolar ablation assembly 52 may be configured in a number of different arrangements to effect bipolar ablation of the underlying tissue. One example is shown in the side view of
In use, the visualization hood 12 is placed against or adjacent to a region of tissue T to be imaged and/or ablated in a body lumen that is normally filled with opaque bodily fluids such as blood. Translucent or transparent fluids 78 which are also electrically conductive, such as saline, may be then introduced into the imaging hood 12 until the transparent fluid 78 displaces the blood thus leaving a clear region of tissue T to be imaged via the imaging element 34 before an ablation process. Upon attaining visual confirmation of the target tissue T surface, RF energy may be generated from power generator 56 such that ablation energy 80 is conducted between central electrode 72 and ring electrode 76 via the saline fluid 78 flowing therebetween in effect ablating the underlying tissue. The saline fluid 78 purged from hood 12 and out through aperture 42 may thus serve multiple functions of clearing blood for visualization, conducting ablative energy, as well as optionally cooling the ablated tissue region to prevent tissue charring, desiccation, or other endothelial disruptions such as “tissue popping”. Other examples of utilizing energy conductive fluid for tissue visualization and ablation are described in further detail in U.S. patent application Ser. No. 12/118,439 filed May 9, 2008 as well as U.S. Prov Pat. App. No. 60/917,487 filed May 11, 2007, each of which is incorporated herein by reference in its entirety.
Another variation is illustrated in the side view of
In another variation,
In another variation,
As illustrated in the side and detail side views of
In yet another variation shown in the side view of
As shown in
Another variation is shown in the side view of
Examples of ablation catheters are shown for illustrative purposes where in one example, the catheter 285 may have a circulating coolant 287 flowing through in a circulating flow pattern. The catheter in this example may include a 7 Fr, 4 mm electrode having a fluid of 5% dextrose circulating at 36 ml/min therethrough. A thermocouple 289 may be positioned within for detecting the electrode temperature. Another example is illustrated where the catheter may define an infusion lumen 291 through which a cooling fluid 293 (e.g., a 7.5 Fr, 3.5 mm electrode with 0.9% NaCl saline infusion) may be flowed through. The electrode distal end may define one or more irrigation lumens 295 through which the cooling fluid may be infused for contacting the underlying tissue (e.g., 6 irrigation holes each having a 0.4 mm diameter). Examples of such ablation catheters may include, though not limited to, commercially available instruments such as the THERMOCOOL® Irrigated tip catheter (Biosense Webster, Inc.), Chilli II™ Cooled Ablation Catheter Boston Scientific, Inc.), or the Cool Path™ Irrigated Tip Ablation Catheter (St. Jude, Inc.). Other configurations may alternatively include the use of a one-way valve in place of the aperture 283 and the use of multiple circumferential balloons attached on the inner wall of the hood inflated around the ablation catheter to isolate saline from ablated tissue.
In the example shown in
In yet another variation,
Another variation is illustrated in the perspective views of
In yet another variation, the tissue visualization and ablation system may be configured as an end effector assembly which may be attachable or coupled to any number of other instruments. An example is shown in the assembly view of
Another variation is shown in the pre-assembly side view of
In yet another variation, an articulatable ablation probe 370, as shown in
The applications of the disclosed invention discussed above are not limited to certain treatments or regions of the body, but may include any number of other treatments and areas of the body. Modification of the above-described methods and devices for carrying out the invention, and variations of aspects of the invention that are obvious to those of skill in the arts are intended to be within the scope of this disclosure. Moreover, various combinations of aspects between examples are also contemplated and are considered to be within the scope of this disclosure as well.
This application claims the benefit of priority to U.S. Prov. Pat. App. 60/971,462 filed Sep. 11, 2007, and is also a continuation-in-part of U.S. patent application Ser. No. 12/201,811 filed Aug. 29, 2008 which claims the benefit of priority to U.S. Prov. Pat. App. 60/969,511 filed Aug. 31, 2007, each of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
623022 | Johnson | Apr 1899 | A |
2305462 | Wolf | Dec 1942 | A |
2453862 | Peter | Nov 1948 | A |
3874388 | King et al. | Apr 1975 | A |
4175545 | Termanini | Nov 1979 | A |
4326529 | Doss et al. | Apr 1982 | A |
4445892 | Hussein et al. | May 1984 | A |
4470407 | Hussein et al. | Sep 1984 | A |
4517976 | Murakoshi et al. | May 1985 | A |
4569335 | Tsuno | Feb 1986 | A |
4576146 | Kawazoe et al. | Mar 1986 | A |
4615333 | Taguchi | Oct 1986 | A |
4619247 | Inoue et al. | Oct 1986 | A |
4676258 | Inokuchi et al. | Jun 1987 | A |
4681093 | Ono et al. | Jul 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4727418 | Kato et al. | Feb 1988 | A |
4784133 | Mackin | Nov 1988 | A |
4848323 | Marijnissen et al. | Jul 1989 | A |
4911148 | Sosnowski et al. | Mar 1990 | A |
4914521 | Adair | Apr 1990 | A |
4943290 | Rexroth et al. | Jul 1990 | A |
4950285 | Wilk | Aug 1990 | A |
4957484 | Murtfeldt | Sep 1990 | A |
4961738 | Mackin | Oct 1990 | A |
4976710 | Mackin | Dec 1990 | A |
4991578 | Cohen | Feb 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
4998916 | Hammerslag et al. | Mar 1991 | A |
4998972 | Chin et al. | Mar 1991 | A |
5047028 | Qian | Sep 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5090959 | Samson et al. | Feb 1992 | A |
5123428 | Schwarz | Jun 1992 | A |
RE34002 | Adair | Jul 1992 | E |
5156141 | Krebs et al. | Oct 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5281238 | Chin et al. | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5306234 | Johnson | Apr 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5330496 | Alferness | Jul 1994 | A |
5334159 | Turkel | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5336252 | Cohen | Aug 1994 | A |
5339800 | Wilta et al. | Aug 1994 | A |
5348554 | Imran et al. | Sep 1994 | A |
5353792 | Lubbers et al. | Oct 1994 | A |
5370647 | Graber et al. | Dec 1994 | A |
5373840 | Knighton | Dec 1994 | A |
5375612 | Cottenceau et al. | Dec 1994 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5403326 | Harrison et al. | Apr 1995 | A |
5405376 | Mulier et al. | Apr 1995 | A |
5421338 | Crowley et al. | Jun 1995 | A |
5431649 | Mulier et al. | Jul 1995 | A |
5453785 | Lenhardt et al. | Sep 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5471515 | Fossum et al. | Nov 1995 | A |
5498230 | Adair | Mar 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5515853 | Smith et al. | May 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5549603 | Feiring | Aug 1996 | A |
5558619 | Kami et al. | Sep 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5575756 | Karasawa et al. | Nov 1996 | A |
5575810 | Swanson et al. | Nov 1996 | A |
5584872 | LaFontaine et al. | Dec 1996 | A |
5591119 | Adair | Jan 1997 | A |
5593422 | Muijs Van de Moer et al. | Jan 1997 | A |
5593424 | Northrup, III | Jan 1997 | A |
5672153 | Lax et al. | Sep 1997 | A |
5676693 | LaFontaine | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5695448 | Kimura et al. | Dec 1997 | A |
5697281 | Eggers et al. | Dec 1997 | A |
5697882 | Eggers et al. | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5713907 | Hogendijk et al. | Feb 1998 | A |
5713946 | Ben-Haim | Feb 1998 | A |
5716321 | Kerin et al. | Feb 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5725523 | Mueller | Mar 1998 | A |
5746747 | McKeating | May 1998 | A |
5749846 | Edwards et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5754313 | Pelchy et al. | May 1998 | A |
5766137 | Omata | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5792045 | Adair | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5823947 | Yoon et al. | Oct 1998 | A |
5827268 | Laufer | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5842973 | Bullard | Dec 1998 | A |
5843118 | Sepetka et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5860974 | Abele | Jan 1999 | A |
5860991 | Klein et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5873815 | Kerin et al. | Feb 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5895417 | Pomeranz et al. | Apr 1999 | A |
5897487 | Ouchi | Apr 1999 | A |
5897553 | Mulier et al. | Apr 1999 | A |
5902328 | LaFontaine et al. | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5929901 | Adair et al. | Jul 1999 | A |
5941845 | Tu et al. | Aug 1999 | A |
5944690 | Falwell et al. | Aug 1999 | A |
5964755 | Edwards | Oct 1999 | A |
5968053 | Revelas | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5986693 | Adair et al. | Nov 1999 | A |
5997571 | Farr et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6012457 | Lesh | Jan 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6027501 | Goble et al. | Feb 2000 | A |
6036685 | Mueller | Mar 2000 | A |
6043839 | Adair et al. | Mar 2000 | A |
6047218 | Whayne et al. | Apr 2000 | A |
6063077 | Schaer | May 2000 | A |
6063081 | Mulier et al. | May 2000 | A |
6068653 | LaFontaine | May 2000 | A |
6071279 | Whayne et al. | Jun 2000 | A |
6071302 | Sinofsky et al. | Jun 2000 | A |
6081740 | Gombrich et al. | Jun 2000 | A |
6086528 | Adair | Jul 2000 | A |
6086534 | Kesten | Jul 2000 | A |
6099498 | Addis | Aug 2000 | A |
6099514 | Sharkey et al. | Aug 2000 | A |
6102905 | Baxter et al. | Aug 2000 | A |
6112123 | Kelleher et al. | Aug 2000 | A |
6115626 | Whayne et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6123718 | Tu et al. | Sep 2000 | A |
6129724 | Fleischman et al. | Oct 2000 | A |
6139508 | Simpson et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6156350 | Constantz | Dec 2000 | A |
6159203 | Sinofsky | Dec 2000 | A |
6161543 | Cox et al. | Dec 2000 | A |
6164283 | Lesh | Dec 2000 | A |
6167297 | Benaron | Dec 2000 | A |
6168591 | Sinofsky | Jan 2001 | B1 |
6168594 | LaFontaine et al. | Jan 2001 | B1 |
6174307 | Daniel et al. | Jan 2001 | B1 |
6178346 | Amundson et al. | Jan 2001 | B1 |
6190381 | Olsen et al. | Feb 2001 | B1 |
6211904 | Adair et al. | Apr 2001 | B1 |
6224553 | Nevo | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6235044 | Root et al. | May 2001 | B1 |
6237605 | Vaska et al. | May 2001 | B1 |
6238393 | Mulier et al. | May 2001 | B1 |
6240312 | Alfano et al. | May 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258083 | Daniel et al. | Jul 2001 | B1 |
6263224 | West | Jul 2001 | B1 |
6270492 | Sinofsky | Aug 2001 | B1 |
6275255 | Adair et al. | Aug 2001 | B1 |
6290689 | Delaney et al. | Sep 2001 | B1 |
6306081 | Ishikawa et al. | Oct 2001 | B1 |
6310642 | Adair et al. | Oct 2001 | B1 |
6311692 | Vaska et al. | Nov 2001 | B1 |
6314962 | Vaska et al. | Nov 2001 | B1 |
6314963 | Vaska et al. | Nov 2001 | B1 |
6315777 | Comben | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6322536 | Rosengart et al. | Nov 2001 | B1 |
6325797 | Stewart et al. | Dec 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6358247 | Altman et al. | Mar 2002 | B1 |
6358248 | Mulier et al. | Mar 2002 | B1 |
6375654 | McIntyre | Apr 2002 | B1 |
6379345 | Constantz | Apr 2002 | B1 |
6385476 | Osadchy et al. | May 2002 | B1 |
6387043 | Yoon | May 2002 | B1 |
6387071 | Constantz | May 2002 | B1 |
6394096 | Constantz | May 2002 | B1 |
6396873 | Goldstein et al. | May 2002 | B1 |
6398780 | Farley et al. | Jun 2002 | B1 |
6401719 | Farley et al. | Jun 2002 | B1 |
6409722 | Hoey et al. | Jun 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6423051 | Kaplan et al. | Jul 2002 | B1 |
6423055 | Farr et al. | Jul 2002 | B1 |
6423058 | Edwards et al. | Jul 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6436118 | Kayan | Aug 2002 | B1 |
6440061 | Wenner et al. | Aug 2002 | B1 |
6440119 | Nakada et al. | Aug 2002 | B1 |
6458151 | Saltiel | Oct 2002 | B1 |
6464697 | Edwards et al. | Oct 2002 | B1 |
6474340 | Vaska et al. | Nov 2002 | B1 |
6475223 | Werp et al. | Nov 2002 | B1 |
6478769 | Parker | Nov 2002 | B1 |
6482162 | Moore | Nov 2002 | B1 |
6484727 | Vaska et al. | Nov 2002 | B1 |
6485489 | Teirstein et al. | Nov 2002 | B2 |
6488671 | Constantz et al. | Dec 2002 | B1 |
6494902 | Hoey et al. | Dec 2002 | B2 |
6497705 | Comben | Dec 2002 | B2 |
6500174 | Maguire et al. | Dec 2002 | B1 |
6502576 | Lesh | Jan 2003 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6517533 | Swaminathan | Feb 2003 | B1 |
6527979 | Constantz et al. | Mar 2003 | B2 |
6532380 | Close et al. | Mar 2003 | B1 |
6533767 | Johansson et al. | Mar 2003 | B2 |
6537272 | Christopherson et al. | Mar 2003 | B2 |
6540733 | Constantz et al. | Apr 2003 | B2 |
6540744 | Hassett et al. | Apr 2003 | B2 |
6544195 | Wilson et al. | Apr 2003 | B2 |
6547780 | Sinofsky | Apr 2003 | B1 |
6558375 | Sinofsky et al. | May 2003 | B1 |
6558382 | Jahns et al. | May 2003 | B2 |
6562020 | Constantz et al. | May 2003 | B1 |
6572609 | Farr et al. | Jun 2003 | B1 |
6579285 | Sinofsky | Jun 2003 | B2 |
6585732 | Mulier et al. | Jul 2003 | B2 |
6587709 | Solf et al. | Jul 2003 | B2 |
6593884 | Gilboa et al. | Jul 2003 | B1 |
6605055 | Sinofsky et al. | Aug 2003 | B1 |
6613062 | Leckrone et al. | Sep 2003 | B1 |
6622732 | Constantz | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6626900 | Sinofsky et al. | Sep 2003 | B1 |
6635070 | Leeflang | Oct 2003 | B2 |
6645202 | Pless et al. | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6659940 | Adler | Dec 2003 | B2 |
6673090 | Root et al. | Jan 2004 | B2 |
6676656 | Sinofsky | Jan 2004 | B2 |
6679836 | Couvillon, Jr. | Jan 2004 | B2 |
6682526 | Jones | Jan 2004 | B1 |
6689128 | Sliwa, Jr. et al. | Feb 2004 | B2 |
6692430 | Adler | Feb 2004 | B2 |
6701581 | Senovich et al. | Mar 2004 | B2 |
6701931 | Sliwa, Jr. et al. | Mar 2004 | B2 |
6702780 | Gilboa et al. | Mar 2004 | B1 |
6704043 | Goldstein et al. | Mar 2004 | B2 |
6706039 | Mulier et al. | Mar 2004 | B2 |
6712798 | Constantz | Mar 2004 | B2 |
6719747 | Constantz et al. | Apr 2004 | B2 |
6719755 | Sliwa, Jr. et al. | Apr 2004 | B2 |
6730063 | Delaney et al. | May 2004 | B2 |
6736810 | Hoey et al. | May 2004 | B2 |
6751492 | Ben-Haim | Jun 2004 | B2 |
6755790 | Stewart et al. | Jun 2004 | B2 |
6755811 | Constantz | Jun 2004 | B1 |
6764487 | Mulier et al. | Jul 2004 | B2 |
6771996 | Bowe et al. | Aug 2004 | B2 |
6773402 | Govari et al. | Aug 2004 | B2 |
6780151 | Grabover et al. | Aug 2004 | B2 |
6805128 | Pless et al. | Oct 2004 | B1 |
6805129 | Pless et al. | Oct 2004 | B1 |
6811562 | Pless | Nov 2004 | B1 |
6833814 | Gilboa et al. | Dec 2004 | B2 |
6840923 | Lapcevic | Jan 2005 | B1 |
6840936 | Sliwa, Jr. et al. | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6858005 | Ohline et al. | Feb 2005 | B2 |
6858026 | Sliwa, Jr. et al. | Feb 2005 | B2 |
6863668 | Gillespie et al. | Mar 2005 | B2 |
6866651 | Constantz | Mar 2005 | B2 |
6887237 | McGaffigan | May 2005 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6899672 | Chin et al. | May 2005 | B2 |
6915154 | Docherty et al. | Jul 2005 | B1 |
6916284 | Moriyama | Jul 2005 | B2 |
6923805 | LaFontaine et al. | Aug 2005 | B1 |
6929010 | Vaska et al. | Aug 2005 | B2 |
6932809 | Sinofsky | Aug 2005 | B2 |
6939348 | Malecki et al. | Sep 2005 | B2 |
6942657 | Sinofsky et al. | Sep 2005 | B2 |
6949095 | Vaska et al. | Sep 2005 | B2 |
6953457 | Farr et al. | Oct 2005 | B2 |
6955173 | Lesh | Oct 2005 | B2 |
6962589 | Mulier et al. | Nov 2005 | B2 |
6971394 | Sliwa, Jr. et al. | Dec 2005 | B2 |
6974464 | Quijano et al. | Dec 2005 | B2 |
6979290 | Mourlas et al. | Dec 2005 | B2 |
6982740 | Adair et al. | Jan 2006 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6994094 | Schwartz | Feb 2006 | B2 |
7019610 | Creighton, IV et al. | Mar 2006 | B2 |
7025746 | Tal | Apr 2006 | B2 |
7030904 | Adair et al. | Apr 2006 | B2 |
7041098 | Farley et al. | May 2006 | B2 |
7042487 | Nakashima | May 2006 | B2 |
7044135 | Lesh | May 2006 | B2 |
7052493 | Vaska et al. | May 2006 | B2 |
7090683 | Brock et al. | Aug 2006 | B2 |
7118566 | Jahns | Oct 2006 | B2 |
7156845 | Mulier et al. | Jan 2007 | B2 |
7163534 | Brucker et al. | Jan 2007 | B2 |
7166537 | Jacobsen et al. | Jan 2007 | B2 |
7169144 | Hoey et al. | Jan 2007 | B2 |
7186214 | Ness | Mar 2007 | B2 |
7207984 | Farr et al. | Apr 2007 | B2 |
7217268 | Eggers et al. | May 2007 | B2 |
7242832 | Carlin et al. | Jul 2007 | B2 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7261711 | Mulier et al. | Aug 2007 | B2 |
7263397 | Hauck et al. | Aug 2007 | B2 |
7276061 | Schaer et al. | Oct 2007 | B2 |
7309328 | Kaplan et al. | Dec 2007 | B2 |
7416552 | Paul et al. | Aug 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7527625 | Knight et al. | May 2009 | B2 |
7534204 | Starksen et al. | May 2009 | B2 |
7569052 | Phan et al. | Aug 2009 | B2 |
7736347 | Kaplan et al. | Jun 2010 | B2 |
7758499 | Adler | Jul 2010 | B2 |
7860555 | Saadat | Dec 2010 | B2 |
7860556 | Saadat | Dec 2010 | B2 |
8131350 | Saadat et al. | Mar 2012 | B2 |
8137333 | Saadat et al. | Mar 2012 | B2 |
20010005789 | Root et al. | Jun 2001 | A1 |
20010020126 | Swanson et al. | Sep 2001 | A1 |
20010039416 | Moorman et al. | Nov 2001 | A1 |
20010047136 | Domanik et al. | Nov 2001 | A1 |
20010047184 | Connors | Nov 2001 | A1 |
20010052930 | Adair et al. | Dec 2001 | A1 |
20020004644 | Koblish | Jan 2002 | A1 |
20020026145 | Bagaoisan et al. | Feb 2002 | A1 |
20020054852 | Cate | May 2002 | A1 |
20020065455 | Ben-Haim et al. | May 2002 | A1 |
20020068853 | Adler | Jun 2002 | A1 |
20020080248 | Adair et al. | Jun 2002 | A1 |
20020087166 | Brock et al. | Jul 2002 | A1 |
20020087169 | Brock et al. | Jul 2002 | A1 |
20020091304 | Takeshi et al. | Jul 2002 | A1 |
20020138088 | Nash et al. | Sep 2002 | A1 |
20020165598 | Wahr et al. | Nov 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20030009085 | Arai et al. | Jan 2003 | A1 |
20030035156 | Cooper | Feb 2003 | A1 |
20030036698 | Kohler et al. | Feb 2003 | A1 |
20030069593 | Tremulis et al. | Apr 2003 | A1 |
20030120142 | Dubuc et al. | Jun 2003 | A1 |
20030130572 | Phan et al. | Jul 2003 | A1 |
20030144657 | Bowe et al. | Jul 2003 | A1 |
20030171741 | Ziebol et al. | Sep 2003 | A1 |
20030181939 | Bonutti | Sep 2003 | A1 |
20030208222 | Zadno-Azizi | Nov 2003 | A1 |
20030212394 | Pearson et al. | Nov 2003 | A1 |
20030216720 | Sinofsky et al. | Nov 2003 | A1 |
20030220574 | Markus et al. | Nov 2003 | A1 |
20030222325 | Jacobsen et al. | Dec 2003 | A1 |
20040006333 | Arnold et al. | Jan 2004 | A1 |
20040049211 | Tremulis et al. | Mar 2004 | A1 |
20040054335 | Lesh et al. | Mar 2004 | A1 |
20040054389 | Osypka | Mar 2004 | A1 |
20040082833 | Adler et al. | Apr 2004 | A1 |
20040097788 | Mourlas et al. | May 2004 | A1 |
20040117032 | Roth | Jun 2004 | A1 |
20040133113 | Krishnan | Jul 2004 | A1 |
20040138707 | Greenhalgh | Jul 2004 | A1 |
20040147806 | Adler | Jul 2004 | A1 |
20040147911 | Sinofsky | Jul 2004 | A1 |
20040147912 | Sinofsky | Jul 2004 | A1 |
20040147913 | Sinofsky | Jul 2004 | A1 |
20040158143 | Flaherty et al. | Aug 2004 | A1 |
20040158289 | Girouard et al. | Aug 2004 | A1 |
20040167503 | Sinofsky | Aug 2004 | A1 |
20040181237 | Forde et al. | Sep 2004 | A1 |
20040199052 | Banik et al. | Oct 2004 | A1 |
20040210239 | Nash et al. | Oct 2004 | A1 |
20040215180 | Starkebaum et al. | Oct 2004 | A1 |
20040215183 | Hoey et al. | Oct 2004 | A1 |
20040220471 | Schwartz | Nov 2004 | A1 |
20040230131 | Kassab et al. | Nov 2004 | A1 |
20040248837 | Raz et al. | Dec 2004 | A1 |
20040254523 | Fitzgerald et al. | Dec 2004 | A1 |
20040260182 | Zuluaga et al. | Dec 2004 | A1 |
20050014995 | Amundson et al. | Jan 2005 | A1 |
20050015048 | Chiu et al. | Jan 2005 | A1 |
20050020914 | Amundson et al. | Jan 2005 | A1 |
20050027163 | Chin et al. | Feb 2005 | A1 |
20050038419 | Arnold et al. | Feb 2005 | A9 |
20050059862 | Phan | Mar 2005 | A1 |
20050059954 | Constantz | Mar 2005 | A1 |
20050059965 | Eberl et al. | Mar 2005 | A1 |
20050065504 | Melsky et al. | Mar 2005 | A1 |
20050090818 | Pike, Jr. et al. | Apr 2005 | A1 |
20050096643 | Brucker et al. | May 2005 | A1 |
20050101984 | Chanduszko et al. | May 2005 | A1 |
20050107736 | Landman et al. | May 2005 | A1 |
20050119523 | Starksen et al. | Jun 2005 | A1 |
20050124969 | Fitzgerald et al. | Jun 2005 | A1 |
20050131401 | Malecki et al. | Jun 2005 | A1 |
20050154252 | Sharkey et al. | Jul 2005 | A1 |
20050158899 | Jacobsen et al. | Jul 2005 | A1 |
20050159702 | Sekiguchi et al. | Jul 2005 | A1 |
20050165279 | Adler et al. | Jul 2005 | A1 |
20050165391 | Maguire et al. | Jul 2005 | A1 |
20050165466 | Morris et al. | Jul 2005 | A1 |
20050182465 | Ness | Aug 2005 | A1 |
20050197530 | Wallace et al. | Sep 2005 | A1 |
20050197623 | Leeflang et al. | Sep 2005 | A1 |
20050215895 | Popp et al. | Sep 2005 | A1 |
20050222557 | Baxter et al. | Oct 2005 | A1 |
20050222558 | Baxter et al. | Oct 2005 | A1 |
20050228452 | Mourlas et al. | Oct 2005 | A1 |
20050234436 | Baxter et al. | Oct 2005 | A1 |
20050234437 | Baxter et al. | Oct 2005 | A1 |
20050267328 | Blumzvig et al. | Dec 2005 | A1 |
20050267452 | Farr et al. | Dec 2005 | A1 |
20060009715 | Khairkhahan et al. | Jan 2006 | A1 |
20060009737 | Whiting et al. | Jan 2006 | A1 |
20060015096 | Hauck et al. | Jan 2006 | A1 |
20060022234 | Adair et al. | Feb 2006 | A1 |
20060025651 | Adler et al. | Feb 2006 | A1 |
20060025787 | Morales et al. | Feb 2006 | A1 |
20060030844 | Knight et al. | Feb 2006 | A1 |
20060069303 | Couvillon et al. | Mar 2006 | A1 |
20060074398 | Whiting et al. | Apr 2006 | A1 |
20060084839 | Mourlas et al. | Apr 2006 | A1 |
20060084945 | Moll et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060111614 | Saadat et al. | May 2006 | A1 |
20060122587 | Sharareh | Jun 2006 | A1 |
20060146172 | Jacobsen et al. | Jul 2006 | A1 |
20060149331 | Mann et al. | Jul 2006 | A1 |
20060155242 | Constantz | Jul 2006 | A1 |
20060161133 | Laird et al. | Jul 2006 | A1 |
20060167439 | Kalser et al. | Jul 2006 | A1 |
20060183992 | Kawashima | Aug 2006 | A1 |
20060184048 | Saadat | Aug 2006 | A1 |
20060217755 | Eversull et al. | Sep 2006 | A1 |
20060224167 | Weisenburgh et al. | Oct 2006 | A1 |
20060253113 | Arnold et al. | Nov 2006 | A1 |
20060258909 | Saadat et al. | Nov 2006 | A1 |
20060271032 | Chin et al. | Nov 2006 | A1 |
20070005019 | Okishige | Jan 2007 | A1 |
20070015964 | Eversull et al. | Jan 2007 | A1 |
20070016130 | Leeflang et al. | Jan 2007 | A1 |
20070043338 | Moll et al. | Feb 2007 | A1 |
20070043413 | Eversull et al. | Feb 2007 | A1 |
20070049923 | Jahns | Mar 2007 | A1 |
20070055142 | Webler | Mar 2007 | A1 |
20070078451 | Arnold et al. | Apr 2007 | A1 |
20070083187 | Eversull et al. | Apr 2007 | A1 |
20070083217 | Eversull et al. | Apr 2007 | A1 |
20070093808 | Mulier et al. | Apr 2007 | A1 |
20070100241 | Adler | May 2007 | A1 |
20070100324 | Tempel et al. | May 2007 | A1 |
20070106146 | Claudio et al. | May 2007 | A1 |
20070106214 | Gray et al. | May 2007 | A1 |
20070106287 | O'Sullivan | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070167801 | Webler et al. | Jul 2007 | A1 |
20070167828 | Saadat | Jul 2007 | A1 |
20070265609 | Thapliyal et al. | Nov 2007 | A1 |
20070265610 | Thapliyal et al. | Nov 2007 | A1 |
20070270686 | Ritter et al. | Nov 2007 | A1 |
20070287886 | Saadat | Dec 2007 | A1 |
20070293724 | Saadat et al. | Dec 2007 | A1 |
20080009747 | Saadat et al. | Jan 2008 | A1 |
20080009859 | Auth et al. | Jan 2008 | A1 |
20080015445 | Saadat et al. | Jan 2008 | A1 |
20080015563 | Hoey et al. | Jan 2008 | A1 |
20080015569 | Saadat et al. | Jan 2008 | A1 |
20080027464 | Moll et al. | Jan 2008 | A1 |
20080033241 | Peh et al. | Feb 2008 | A1 |
20080033290 | Saadat et al. | Feb 2008 | A1 |
20080057106 | Erickson et al. | Mar 2008 | A1 |
20080058590 | Saadat et al. | Mar 2008 | A1 |
20080058650 | Saadat et al. | Mar 2008 | A1 |
20080058836 | Moll et al. | Mar 2008 | A1 |
20080097476 | Peh et al. | Apr 2008 | A1 |
20080183081 | Lys et al. | Jul 2008 | A1 |
20080188759 | Saadat et al. | Aug 2008 | A1 |
20080214889 | Saadat et al. | Sep 2008 | A1 |
20080228032 | Starksen et al. | Sep 2008 | A1 |
20080275300 | Rothe et al. | Nov 2008 | A1 |
20080281293 | Peh et al. | Nov 2008 | A1 |
20080287790 | Li | Nov 2008 | A1 |
20080287805 | Li | Nov 2008 | A1 |
20090030276 | Saadat et al. | Jan 2009 | A1 |
20090030412 | Willis et al. | Jan 2009 | A1 |
20090054803 | Saadat et al. | Feb 2009 | A1 |
20090062790 | Malchano et al. | Mar 2009 | A1 |
20090076489 | Welches et al. | Mar 2009 | A1 |
20090076498 | Saadat et al. | Mar 2009 | A1 |
20090082623 | Rothe et al. | Mar 2009 | A1 |
20090125022 | Saadat et al. | May 2009 | A1 |
20090143640 | Saadat et al. | Jun 2009 | A1 |
20090187074 | Saadat et al. | Jul 2009 | A1 |
20090203962 | Miller et al. | Aug 2009 | A1 |
20090221871 | Peh et al. | Sep 2009 | A1 |
20090227999 | Willis et al. | Sep 2009 | A1 |
20090264727 | Markowitz et al. | Oct 2009 | A1 |
20090267773 | Markowitz et al. | Oct 2009 | A1 |
20090275799 | Saadat et al. | Nov 2009 | A1 |
20090275842 | Saadat et al. | Nov 2009 | A1 |
20090299363 | Saadat et al. | Dec 2009 | A1 |
20090326572 | Peh et al. | Dec 2009 | A1 |
20100004506 | Saadat et al. | Jan 2010 | A1 |
20100004633 | Rothe et al. | Jan 2010 | A1 |
20100004661 | Verin et al. | Jan 2010 | A1 |
20100010311 | Miller et al. | Jan 2010 | A1 |
20100094081 | Rothe et al. | Apr 2010 | A1 |
20100130836 | Malchano et al. | May 2010 | A1 |
20110060227 | Saadat | Mar 2011 | A1 |
20110060298 | Saadat | Mar 2011 | A1 |
20110144576 | Rothe et al. | Jun 2011 | A1 |
20120016221 | Saadat et al. | Jan 2012 | A1 |
20120059366 | Drews et al. | Mar 2012 | A1 |
Number | Date | Country |
---|---|---|
10028155 | Dec 2000 | DE |
0283661 | Sep 1988 | EP |
0301288 | Feb 1999 | EP |
59093413 | May 1984 | JP |
59-181315 | Oct 1984 | JP |
01-221133 | Sep 1989 | JP |
03-284265 | Dec 1991 | JP |
05-103746 | Apr 1993 | JP |
09-051897 | Feb 1997 | JP |
11-299725 | Nov 1999 | JP |
2001-258822 | Sep 2001 | JP |
WO 9221292 | Dec 1992 | WO |
WO 9407413 | Apr 1994 | WO |
WO 9503843 | Feb 1995 | WO |
WO 9818388 | May 1998 | WO |
WO 03039350 | May 2003 | WO |
WO 03053491 | Jul 2003 | WO |
WO 03101287 | Dec 2003 | WO |
WO 2004043272 | May 2004 | WO |
WO 2004080508 | Sep 2004 | WO |
WO 2005070330 | Aug 2005 | WO |
WO 2005077435 | Aug 2005 | WO |
WO 2005081202 | Sep 2005 | WO |
WO 2006017517 | Feb 2006 | WO |
WO 2006024015 | Mar 2006 | WO |
WO 2006083794 | Aug 2006 | WO |
WO 2006091597 | Aug 2006 | WO |
WO 2006126979 | Nov 2006 | WO |
WO 2007067323 | Jun 2007 | WO |
WO 2007079268 | Jul 2007 | WO |
WO 2007133845 | Nov 2007 | WO |
WO 2007134258 | Nov 2007 | WO |
WO 2008015625 | Feb 2008 | WO |
WO 2008021994 | Feb 2008 | WO |
WO 2008021997 | Feb 2008 | WO |
WO 2008021998 | Feb 2008 | WO |
WO 2008024261 | Feb 2008 | WO |
WO 2008079828 | Jul 2008 | WO |
WO 2009112262 | Sep 2009 | WO |
Number | Date | Country | |
---|---|---|---|
20090076498 A1 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
60971462 | Sep 2007 | US | |
60969511 | Aug 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12201811 | Aug 2008 | US |
Child | 12209057 | US |